Glaxo to Sell Rare Disease Gene Therapies to Private Biotech – Zacks.com
Zacks.com |
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
Zacks.com Glaxo’s rare disease gene therapies include marketed drug Strimvelis, a gene therapy for children with ADA-SCID which is an autosomal recessive metabolic disorder that causes immunodeficiency, along with some pipeline candidates including late-stage … Orchard Therapeutics to buy GSK’s rare disease gene therapy portfolioPharmaceutical Business Review Gene Therapy and Antisense Drugs Developing New Market By 2025Pharmaceuticals News Gene Therapy Market Overview, Type, Manufacturers, Regions, Industry Analysis and Forecast by 2022Healthcare Journal |
|
Immunotherapy could hold the key to eradicating cancer, but what is it and how does it work?
Alphr In some medical circles, immunotherapy is heralded as a wonder treatment; a technique that could fight multiple diseases and conditions by leveraging the body’s own immune system. It is most commonly known in relation to cancer treatment, but it’s also … Cancer Immunotherapy Market: By Key Players, Types, Application, Market Competitive Landscape, Trends and …Pharmaceuticals News |
Drug Target Review |
Disrupting macrophage action aids melanoma immunotherapy success
Drug Target Review Immunotherapies are treatments that stimulate a patient’s immune cells to attack tumours. They can be very effective in melanoma – a common and aggressive form of skin cancer – but still fail in the majority of patients. To address this, researchers … |
|
Baylor University Medical Center Begins Breakthrough CAR–T Cancer Treatment for Patients with Non-Hodgkin’s …
Newswise (press release) Chimeric Antigen Receptor T cell therapy, or CAR-T, is a personalized therapy where a patient’s own immune cells are removed from the patient’s body, genetically reprogrammed, then infused back into the patient to identify and attack their cancer as a … |
|
Baylor University Medical Center Begins Breakthrough CAR–T Cancer Treatment for Patients with Non-Hodgkin’s …
Newswise (press release) Chimeric Antigen Receptor T cell therapy, or CAR-T, is a personalized therapy where a patient’s own immune cells are removed from the patient’s body, genetically reprogrammed, then infused back into the patient to identify and attack their cancer as a … |
STAT |
In a bid to promote stem cell therapies, health officials open a new door for promising contenders
STAT OUSTON — When someone experiences a severe head injury, it’s not just the initial blow that batters the brain. The body’s immune response can go haywire, overwhelming and sometimes continuing to damage the brain for months. Surgeons at Houston’s … Animal Stem Cell Therapy Market Global Analysis by 2023: Celavet, Magellan Stem Cells, US Stem Cell and J-ARMHealthcare Journal |
Pharmaceutical Business Review |
Orchard Therapeutics to buy GSK’s rare disease gene therapy portfolio
Pharmaceutical Business Review The acquisition of the portfolio, which includes both approved and investigational therapies like Strimvelis and a therapy for beta thalassaemia, is expected to consolidate Orchard’s position in gene therapy for rare diseases. Orchard also expects the … Gene Therapy and Antisense Drugs Developing New Market By 2025Pharmaceuticals News |